Aman Fills Its Last Blank Spot on the Map: Maldives
Aman has confirmed Amanolu, its first Maldives property, set to open in 2028. It closes a notable gap for a brand whose portfolio spans nearly every other ultra-luxury wellness geography, and gives advisors a new anchor property to fold into future Indian Ocean itineraries once details on villa count and rates emerge.
The 2028 date means there's no booking window yet, but it's worth flagging to longevity- and wellness-minded clients now. Aman's inaugural inventory has historically sold through fast — Amanoi, Amangiri and others opened to strong early demand — so advisors who track allocation and pre-opening rate releases as they surface will be positioned ahead of the rush rather than reacting to a sold-out calendar once the resort is closer to opening.
The Numbers Behind the Medical-Spa Pivot
Two data points landed this week that quantify what advisors have been feeling anecdotally. Global Wellness Institute tracking shows spa revenue climbing from $47B in 2007 to $157B in 2024 — a 7.4% CAGR — inside a $6.8T wellness economy GWI projects reaching $9.8T by 2029. Separately, a new report maps more than 3,000 longevity therapeutic assets in development, sizing the longevity biotech pipeline at $617B by 2045.
Read together, they support a repositioning already underway at properties like SHA Wellness, Lanserhof, Clinique La Prairie, Mayrlife and Palace Merano: away from leisure-spa framing and toward clinical, diagnostic-driven programming. For advisors, that's justification to price and pitch longevity retreats as a structural category rather than a discretionary upgrade.